Navigation Links
Penn researchers successfully alleviate pulmonary inflammation with targeted drug delivery

(PHILADELPHIA) Pulmonary inflammation can cause shallow breathing and the lungs to become brittle in patients who experience multiple blood transfusions, sepsis, lung surgery and acute lung trauma. This complication can leave patients on ventilators, which can further traumatize the lungs, and often results in a mortality rate of 30 to 40 percent. To date, no medication has been successful at preventing or mitigating the damage caused by lung inflammation. Now, a multidisciplinary research team led by David Eckmann, MD, PhD, Horatio C. Wood Professor of Anesthesiology and Critical Care at the Perelman School of Medicine at the University of Pennsylvania and professor of Bioengineering in Penn's School of Engineering and Applied Science, has found that when delivered by a microscopic transporter called a nanocarrier, steroids can access the hard-to-reach lung endothelial cells that need it most and are successful at preventing inflammation in mice. This proof-of-concept study is published in PLOS One.

"This is a treatment that benefits entirely from targeted delivery or it tends not to have any significant therapeutic benefit," says Eckmann.

"That's part of the challenge with this disorder: we have been uncertain to this point whether it was the medication or its delivery mechanism that wasn't working. Our results in mouse models show beyond a shadow of a doubt that the drugs can be effective, we just needed to improve delivery," says Eckmann. Acute lung injury develops as a result of direct or indirect trauma to the lungs. It compromises the hard-to-reach pores that enable gas exchange between the epithelial and endothelial barriers in the lungs.

During the past year the team was awarded an National Science Foundation and two NIH grants to design nanocarriers for targeted drug delivery through a combination of computer modeling and laboratory experiments. This study represents the first of their experimental results.

The team used a nanogel, a specialized nanocarrier, for drug delivery made up of two moleculesdextran (a sugar) and lysozyme (a protein)which mesh into a spaghetti-like ball that can fill with water to expand and contract. A specific lung-targeting molecule is attached to the carrier's surface and the steriod, dexamethasone, an anti-inflammatory, is loaded into the nanogel, which then binds to lung endothelial cells lining the inside wall of the blood vessels where it rapidly delivers the drug.

"This molecule on the surface of the nanocarrier has specialized preference for the lung to enhance localized and targeted drug delivery," says Eckmann.

The team next plans to try the therapy in a cohort of patients at the Hospital of the University of Pennsylvania.


Contact: Lee-Ann Donegan
University of Pennsylvania School of Medicine

Related biology technology :

1. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
2. In new quantum-dot LED design, researchers turn troublesome molecules to their advantage
3. Multidisciplinary team of researchers develop world’s lightest material
4. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
5. Innovative MetaMorph® NX Software Shatters Barriers Between Researchers and Image Analysis Goals with Exclusive Visual Workflow
6. UCLA researchers demonstrate fully printed carbon nanotube transistor circuits for displays
7. Penn and Brown researchers demonstrate earthquake friction effect at the nanoscale
8. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public
9. Researchers develop one of the worlds smallest electronic circuits
10. MU researchers identify key plant immune response in fight against bacteria
11. Researchers realize high-power, narrowband terahertz source at room temperature
Post Your Comments:
Related Image:
Penn researchers successfully alleviate pulmonary inflammation with targeted drug delivery
(Date:10/12/2017)... Iowa (PRWEB) , ... October 12, 2017 , ... ... based in Vilnius, Lithuania, announced today that they have entered into a multiyear ... is to provide CRISPR researchers with additional tools for gene editing across all ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global contract research, ... improve patient outcomes and quality of life, will now be offering its impurity ... to new regulatory requirements for all new drug products, including the finalization of ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... pathology, announced today it will be hosting a Webinar titled, “Pathology is going ... Pathology Associates , on digital pathology adoption best practices and how Proscia improves ...
Breaking Biology Technology:
(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017  Socionext Inc., a ... prototype of a media edge server, the M820, which features the ... face recognition software provided by Tera Probe, Inc., will be showcased ... and at the NAB show at the Las Vegas ... ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... to grow at a CAGR of 30.37% during the period 2017-2021. ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
Breaking Biology News(10 mins):